Phosphodiesterase 5 (PDE5) inhibitors can be used for the treatment of erectile dysfunction and pulmonary hypertension. In order to search for new leads of PDE5 inhibitors, we investigated the chemical constituents of the tubers of Eulophia macrobulbon (E.C. Parish & Rchb. f.) Hook. f. A new phenanthrene, 9,10-dihydro-4-(4-hydroxybenzyl)-2,5-dimethoxyphenanthrene-1,7-diol (1) and three known phenanthrenes i.e., 1-(4-hydroxybenzyl)-4,8dimethoxyphenanthrene-2,7-diol (2), (9,10-dihydro-2,5-dimethoxyphenanthrene-1,7-diol (3) and 1,5,7-trimethoxyphenanthrene-2,6-diol) (4) were isolated. Among these, 2 was the most potent PDE5 inhibitor (IC 50 =1.67±0.54 µM) evaluated by the [ 3 H]cGMP radioassay method, whereas 1 showed mild activity (IC 50 = 62.3±3.3 µM). Their inhibitory selectivities against PDE5 over PDE6 were also studied. This study suggests phenanthrenes as a new class of PDE5 inhibitors.
Erectile dysfunction (ED) is the inability to achieve or sustain penile erection [1] [2] [3] [4] and causes low self-esteem. Its prevalence is associated with aging and in the US 18 million men are affected [5] and the number is predicted to grow to 300 million globally by 2025 [6] . In Brazil, 45% of the male population over 18 years have some degree of ED [7] . PDE5 inhibitors, sildenafil (Viagra ® ), vardenafil (Levirate ® ), tadalafil (Cialis ® ) and Avanafil (Stendra ® ) have become first-line treatments [8] [9] [10] [11] . The most important sideeffects of PDE5 inhibitors is retinal defects via PDE6 inhibition [12] [13] [14] . Consequently, the search continues for both synthetic and herbal PDE5 inhibitors having high selectivity. We have screened Thai medicinal plants for PDE5 inhibitory activity, and Eulophia macrobulbon (E.C. Parish & Rchb. f.) Hook. f., a plant belonging to the Orchidaceae family, showed promising PDE5 inhibition. The present study aimed to isolate the biologically active phytochemicals of this plant, which hitherto have not been reported.
The separation of E. macrobulbon tuber extracts yielded four compounds ( Figure 1 ). The HREIMS data of compound 1 exhibited a molecular ion peak at m/z 378.1478, which represented [MH] + for C 23 H 22 O 5 . Its IR spectrum showed a typical characteristic band of a hydroxyl group at 3338 (O-H stretching) and aromatic bands at 1614, and 1516 cm -1 (C=C stretching). Its 13 C NMR spectrum in MeOH-d 4 showed 21 resonances, which represented 23 carbon atoms. These were determined as two methyls, three methylenes, seven aromatic methines and eleven aromatic quaternary carbons by DEPT and HSQC experiments. The 1 H NMR spectrum indicated resonances for four protons at  2.04, 3.20, 2.38, and 2.61 (ddd), which are typical for methylene protons of a 9,10-dihydrophenanthrene derivative. Two methoxyl resonances were observed at  3.62 and 3.69. One singlet aromatic proton signal at  6.47 was found and a pair of doublets at  6.36 and 6.38 with a coupling The presence of two doublets for a benzylic-CH 2 at  3.72 and 3.81 (J = 15.0 Hz) indicated a benzyl substitution. Two doublets (2H) at  6.81 and 6.61 with ortho coupling constants of 8.4 Hz were assigned to H-2/H-6 and H-3/H-5, respectively. These data suggested a para-disubstituted benzene. The 1 H and 13 C NMR assignments were based on HMBC and NOESY experiments ( Figure 2) . The presence of a cross peak between H-3 and the benzylic-CH 2 in the HBMC experiment supported the connectivity between the 4 hydroxybenzyl group and the phenanthrene structure at C-4. The methoxy group positions in the structure were assigned using NOESY. The methoxy at  3.62 was located at C-5 since it displayed cross peaks with H-6, while the other methoxy ( 3.69) showed a cross peak with H-3 in the NOESY experiment, suggesting that it was located at C-2. Finally, compound 1 was unambiguously identified as 9,10-dihydro-4-(4-hydroxybenzyl)- 2,5-dimethoxyphenanthrene-1,7-diol, a new 9,10-dihydrophenanthrene derivative. The structures of 2, 3 and 4 were identified by spectroscopy and by comparing with published spectroscopic data [15] [16] [17] [18] .
Phenanthrene compounds 1, 2 and 4 showed >70% inhibition against both PDE5 and PDE6 at 50 g/mL (Table 1 ). Compound 2, the main constituent, was the most potent PDE5 and PDE6 inhibitor, but less than sildenafil ( Table 2 ). Even though PDE5/PDE6 selectivities were poor, they showed high selectivity over PDE1, which is abundant in the heart [19] . This appears to be the first study reporting phenanthrenes inhibiting PDEs and pharmacologically-active constituents of E. macrobulbon. Phenanthrenes may offer leads to synthesize more potent and selective PDE5 inhibitors. The limited number of compounds restricted interpretation of structure activity relationships. Nevertheless, the aromaticity of these compounds might be important for PDE5 and PDE6 inhibitory activities. Other Eulophia spp. studied have been E. nuda [15] [16] [20] [21] [22] , E. petersii [23] and E. ochreata [24] [25] , which also contain phenanthrenes. Their pharmacological properties include tumor cytotoxicity, and platelet anti-aggregation, anti-microbial, anti-inflammatory, and spasmolytic actions [22, 26] . PDE inhibition might underlie some actions, particularly those on smooth muscle. [27] and Huang et al. [28] , respectively, similar to that for PDE5, but with Ca-calmodulin and histone in Reagent A. The PDE1 assay needed CaCl 2 (0.8 mM) and calmodulin (4 µg/mL) while histone (0.5 mg/mL) was needed for PDE6. In preliminary screening, 50 g/mL of plant extracts was tested and pure compounds tested at 10 M final conc. All samples were dissolved in DMSO and diluted with water. DMSO was limited to 1% in the final assay medium. In the case of > 80% PDE inhibition, the IC 50 values were measured by the determinations of serial concentrations of the samples. The IC 50 values were calculated using Prism software (Graph Pad Inc., San Diego, CA). Sildenafil was the positive control.
